GALLIMUNE 303 ND+IB+ART Water-in oil emulsion for injection

Authorised

- Turkey rhinotracheitis virus, strain VCO3, Inactivated
- Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Newcastle disease virus, strain Ulster 2C, Inactivated

Product identification

Medicine name:
GALLIMUNE 303 ND+IB+ART Water-in oil emulsion for injection
Gallimune 303 ND+IB+ART

Active substance:
Turkey rhinotracheitis virus, strain VCO3, Inactivated

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

Newcastle disease virus, strain Ulster 2C, Inactivated

Target species:
Chicken (for reproduction)

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Turkey rhinotracheitis virus, strain VCO3, Inactivated

0.76 interference percentage unit(s) / 0.30 millilitre(s)

Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
18.00 log10 haemagglutination inhibiting unit(s) / 0.30 millilitre(s)

Newcastle disease virus, strain Ulster 2C, Inactivated
50.00 50% Protective Dose / 0.30 millilitre(s)

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Chicken (for reproduction)**
  - Egg. 0 day
  - Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AA21

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Germany

Package description:
(ID4): 1 Box with 10 Bottle (PolyPropylene) with 300 millilitre(s) (3000 millilitre(s))
(ID3): 1 Box with 1 Bottle (PolyPropylene) with 300 millilitre(s) (300 millilitre(s))
(ID2): 1 Box with 10 Bottle (PolyPropylene) with 150 millilitre(s) (1500 millilitre(s))
(ID1): 1 Box with 1 Bottle (PolyPropylene) with 150 millilitre(s) (150 millilitre(s))

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
15/05/2000

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.01041.01.1

Date of authorisation status change:
29/04/2009

Reference member state:
Germany

Procedure number:
DE/V/0228/001

Concerned member states:
Belgium Cyprus Denmark Finland France Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Portugal Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 15/02/2024
Download
